Uses of Lipanthyl Supra 160mg

This is an automatically translated article.

1. What is Lipanthyl Supra 160mg?

Lipanthyl Supra 160mg has the ingredient fenofibrate 160mg. Fenofibrate is a fibric acid derivative that alters lipid levels through activation of peroxisome proliferative receptor alpha (PPARα). With this mechanism, Fenofibrate increases lipolysis, the excretion of triglyceride-rich particles from the plasma. Fenofibrate increases HDL (good cholesterol) and lowers LDL (bad cholesterol). Besides, Fenofibrate also has other effects such as: Reducing tendons or tumors in jaundice, increasing urinary uric acid excretion, antiplatelet drugs.
Indications for use of Lipanthyl Supra 160mg:
Treatment of hypercholesterolemia or hypertriglyceridemia in patients unresponsive to diet or other non-pharmacological treatments (weight loss, increased physical activity) ), especially when there are other health risks associated with it; Treat secondary hyperlipoproteinemia if persistent lipoprotein abnormalities are present (despite treatment of the underlying cause, eg dyslipidemia in diabetics). Contraindications to using Lipanthyl Supra 160mg:
Children; Pregnant and lactating women; Patients with liver failure (abnormal liver function, biliary cirrhosis); Patients with severe renal impairment (creatinine clearance less than 20ml/min); Patients with hypersensitivity to any component of Fenofibrate or excipients; People with a history of allergic reactions to light, phototoxicity while using fenofibrate or with Ketoprofen, acute or chronic pancreatitis (except in cases of pancreatitis due to high blood lipids), gallbladder fossa disease,. ..; People who are allergic to peanuts, peanut oil, soy lecithin or preparations from this material.

2. Usage and dosage of Lipanthyl Supra 160mg

Usage: Orally. Patients should take Lipanthyl Supra 160mg after meals.
Dosage: Recommended to use 1 tablet / day.
Overdose: There are currently no reports of an overdose of Lipanthyl Supra 160mg and there is no specific antidote. If an overdose is suspected, the patient should be hospitalized immediately for symptomatic and supportive treatment.
Missed dose: If you miss a dose of Lipanthyl Supra 160mg, the patient should take it as soon as possible. However, if it is almost time for the next dose, the patient should skip the missed dose and take the next dose as scheduled.

3. Side effects of Lipanthyl Supra 160mg

When using Lipanthyl Supra 160mg, patients may experience some side effects such as:
Common: Digestive disorders, stomach - intestines (abdominal pain, nausea, vomiting, diarrhea, flatulence) ) moderate, moderately elevated serum transaminase levels; Uncommon: Pancreatitis, gallstone enlargement, urticaria, skin pruritus, rash, diffuse myalgia, myalgia, muscle cramps, muscle weakness, fibromyalgia, thromboembolic disease (deep vein thrombosis, embolism) lungs), headache, physiological decline, increased serum creatinine and urea, increased blood homocysteine ​​levels; Rare: Hair loss, growth of blisters or lumps on skin exposed to sunlight or ultraviolet light, skin sensitivity to light, decreased hemoglobin and white blood cells; Very rare: Hepatitis; Frequency not determined: Paroxysmal myoglobinuria, interstitial lung disease. When experiencing side effects of Lipanthyl Supra 160mg, patients should notify their doctor for appropriate intervention.

4. Be careful when using Lipanthyl Supra 160mg

Some notes patients need to remember before and while using Lipanthyl Supra 160mg:
For cases of secondary hypercholesterolemia such as uncontrolled type 2 diabetes, nephrotic syndrome, hypothyroidism, liver disease Obstruction under treatment, dysproteinemia, alcoholism,... should be treated appropriately before taking Fenofibrate; The patient's response to treatment should be monitored by determination of serum lipid values ​​(total cholesterol, LDL-cholesterol and triglycerides), if response is not achieved after several months, additional consideration should be given to alternative therapy. other position; For patients with high blood lipids who are using estrogen or estrogen-containing contraceptives, it is necessary to determine whether the cause of hyperlipidemia is primary or secondary (may have increased blood fat due to taking estrogen); There have been cases of increased transaminase levels in some liver diseases. Most cases are transient, mild, and almost asymptomatic. Transaminase levels should be monitored periodically every 3 months for the first 12 months of drug therapy, then periodically. Attention should be paid to patients with progressive elevations in transaminase levels, and treatment should be discontinued if ALT and AST levels rise more than 3 times the upper limit of normal; Pancreatitis has been reported with the use of Fenofibrate. This may be due to drug failure in patients with severe hypertriglyceridemia, or a therapeutic phenomenon secondary to biliary stones, bile duct deposits; Myotoxicity (including urinary muscle globin) has been reported with fenofibrate and other lipid-lowering agents. The incidence of this disorder is increased in patients with hypoalbuminemia and pre-existing renal failure. The risk of urinary muscle globin is increased in patients who are over 70 years old, have a personal or family history of hereditary muscle disorders, hypothyroidism, kidney failure, heavy alcohol consumption, etc. consider the benefits and risks when using fenofibrate for these subjects. Myotoxicity must be considered when the patient has diffuse myalgia, myositis accompanied by convulsions in the painful muscle, muscle weakness, cramps, increased CPK (concentration above 5 times normal level). In this case, treatment with fenofibrate should be discontinued; There is an increased risk of myotoxicity when fenofibrate is used concomitantly with other fibrates or HMG-CoA reductase inhibitors (especially if pre-existing myopathy is present). Therefore, caution should be exercised when prescribing fenofibrate with other fibrates or HMG-CoA reductase inhibitors to patients without a history of myopathy but with severe dyslipidemia associated with a high CVD risk. The possibility of muscle toxicity should be closely examined; Elderly people can use the drug Fenofibrate equal to the adult dose; Lipanthyl Supra 160mg contains lactose, so it should not be used for people with lactase deficiency, galactose intolerance or galactose malabsorption; Fenofibrate should be discontinued in the event that the patient develops an increase in creatinine levels above 50% of the upper limit or normal. Creatinine should be measured during the first 3 months of taking the drug; There are no adequate data on the use of fenofibrate in pregnant women, and should only be used during pregnancy after a thorough assessment of the benefits and risks; There are no data on the excretion of Fenofibrate into breast milk. Therefore, this subject should not take Fenofibrate while breastfeeding.

5. Drug interactions Lipanthyl Supra 160mg

Some drug interactions of Lipanthyl Supra 160mg include:
It is not recommended to combine Fenofibrate (the main ingredient of Lipanthyl Supra 160mg) with oral anticoagulants. Fenofibrate enhances the effect of anticoagulants, increasing the risk of bleeding. However, if co-administration is required, the anticoagulation dose should be reduced by 1⁄3 at initiation of therapy, then gradually adjusted if necessary to the international standard ratio (INR); There have been a few cases of reversible decline in renal function with concomitant use of fenofibrate and cyclosporin. Renal function should be closely monitored, treatment with fenofibrate should be discontinued in case patients have severe changes in laboratory parameters; HMG-CoA reductase inhibitors and fibrates may increase the risk of myotoxicity if used concomitantly with fenofibrate. Therefore, these combination therapies should be used with caution and closely monitored for signs of muscle toxicity; At therapeutic concentrations, fenofibrate is a weak inhibitor of CYP2C19 and CYP2A6, a mild-moderate inhibitor of CYP2C9. Patients receiving fenofibrate concomitantly with drugs metabolised by CYP2C19, CYP2A6 and CYP2C9 should be closely monitored. Dosage adjustment of these drugs is recommended if necessary. Patients should strictly follow the doctor's instructions during treatment with Lipanthyl Supra 160mg. If you experience any unusual side effects, the patient should immediately notify the doctor to receive appropriate advice and intervention.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.